Equitable (EQH) Q4 2025 Earnings Transcript

Equitable reported 2025 non-GAAP operating EPS of $6.21 excluding notable items, up 1%, and guided to earnings growth above its 12%-15% target in 2026 as organic cash generation rises to about $1.8B. Assets under management/administration hit a record $1.1T, shareholder returns reached $1.8B with a 95% payout ratio including buybacks, and the RGA reinsurance deal freed $2B of capital while reducing mortality exposure by 75%. Offsetting the positives, AllianceBernstein posted $11.3B of net outflows and corporate/other faces a $350M-$400M loss outlook tied to higher mortality assumptions.

Analysis

EQH is starting to behave less like a mortality-sensitive insurer and more like a compounding fee/spread platform with an embedded capital-return machine. The key second-order effect is that the RGA deal did not just de-risk earnings; it also converted a volatile balance-sheet story into a cleaner equity-duration story, which should matter disproportionately to the multiple because the remaining driver set is now AUM, flows, and buybacks rather than claims noise. That combination can close part of the valuation gap versus AB if management keeps converting cash into repurchases at depressed multiples.

The market is likely still underappreciating how much the company can self-fund growth without stretching capital. With organic cash generation rising toward $1.8B next year and share count already down 9%, EPS can accelerate even if operating momentum is only mid-single-digit in the core businesses. The hidden lever is that capital released from low-volatility runoff and reinsurance can be recycled into higher-return distribution, private markets, and adviser assets; that is a structurally better use of capital than sitting on excess RBC.

The main risk is that investors overfocus on the headline mortality and miss that the real sensitivity is fee/market beta plus competitive intensity in RILA. If rates fall faster than assumed or equity markets weaken, the near-term uplift from AUM and spread income slows, and the stock could remain cheap longer than fundamentals imply. Still, the setup is better on a 6-12 month horizon than a 1-2 month horizon because the 2026 guide is effectively a reset point with a cleaner comparison base and lower tail-risk from claims.

Contrarian angle: the consensus appears to treat EQH as a noisy insurer with a private-credit overhang, but the private-credit exposure is small enough that it is more narrative than balance-sheet risk. The more important debate is whether AB's outflows and EQH's own growth can coexist; if AB private markets and insurance-asset wins keep scaling, the flywheel can offset muted traditional asset-management flows. That makes this more of a cash-compounding and capital-allocation story than a pure asset-gathering story.

Key Decisions for Investors

• Long EQH common for 6-12 months: favor on cash-generation and buyback torque; downside is limited if earnings merely track guide, while upside is multiple re-rating if mortality noise fades.
• Pair trade: long EQH / short a more mortality-exposed life carrier over the next 2 quarters; EQH has cleaner EPS acceleration and a stronger buyback bid, while the short leg remains vulnerable to claim volatility.
• Use weakness to buy EQH call spreads expiring after the next two quarters; the trade is a cleaner expression of guide credibility and share-count reduction than owning outright into near-term volatility.
• Relative value: long EQH vs short AB only if you want to isolate the valuation-discount thesis; EQH offers better capital return, but AB has higher direct market beta, so size tightly and expect the pair to be noisy.
• Avoid shorting EQH solely on private-credit headlines; the better catalyst to fade is a risk-off market selloff, not credit-specific stress, because the disclosed exposure is not large enough to drive fundamental impairment quickly.